LTRN
NASD Lantern Pharma, Inc.$0.9401 ↑ +0.0000 (+0.00%) Trading Up from the previous close of $0.9401, $0.0299 below the day’s high of $0.9700
- YTD change
- -68.97%
- vs 20-day SMA
- -35.85%
- vs 200-day SMA
- -65.48%
Price ranges
Price & Performance
-0.76 (-46.91%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 96.2% away from all-time highs of $24.8400
- LTRN is down 69% since the beginning of the year
- LTRN is down 77% over the past 12 months
- LTRN is down 50% over the past 1 month
- 5% of all LTRN investors are betting against LTRN
LTRN reads poor: price sits below both the 20- and 200-day averages, the 12-month move is -80.5%.
- Previous minute
- +$0.0000
- Last hour
- -$0.0099
- Last 5 days
- -22.94%
- vs 8-day SMA
- -15.16%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
Lantern Pharma, Inc. engages in the development of drugs through leveraging artificial intelligence, machine learning, and genomic data. Its portfolio includes LP-100, LP-300, and LP-184. The company was founded by Arun K. Asaithambi, Gregory T. Tobin, and Peter L. Nara on November 7, 2013 and is headquartered in Dallas, TX.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.
